Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

40.05 +0.06 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,432,724
Open 41.01
Bid (Size) 39.90 (1)
Ask (Size) 40.20 (1)
Prev. Close 39.99
Today's Range 39.96 - 44.14
52wk Range 34.10 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts
Via Benzinga

Performance

YTD
-67.7%
-67.7%
1 Month
-27.5%
-27.5%
3 Month
-62.6%
-62.6%
6 Month
-63.9%
-63.9%
1 Year
-69.0%
-69.0%

More News

Read More
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays
Via StockStory
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
From Sarepta Therapeutics, Inc.
Via Business Wire
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Via MarketBeat
Topics Earnings
Exposures Financial Product Safety
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
Via Benzinga
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
Via The Motley Fool
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
Via Benzinga
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why
Via StockStory
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
Via Benzinga

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 40.05
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 05/21/25 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 3.73B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.